Halozyme Therapeutics reported $47.32M in Cost of Sales for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Cost Of Sales Change
Acadia Pharmaceuticals ACAD:US USD 2.14M 531K
Agios Pharmaceuticals AGIO:US USD 517K 82K
Alnylam Pharmaceuticals ALNY:US USD 41.12M 308K
Amarin AMRN:US USD 23.94M 11.87M
Amgen AMGN:US USD 1.59B 78M
Baxter International BAX:US USD 2.63B 337M
Cara Therapeutics CARA:US USD 3.06M 3.06M
Eli Lilly And LLY:US USD 1.58B 148.6M
Esperion Therapeutics ESPR:US USD 6.51M 2.67M
Halozyme Therapeutics HALO:US USD 47.32M 13.38M
Intercept Pharmaceuticals ICPT:US USD 424K 115K
Intra Cellular Therapies ITCI:US USD 5.85M 1.2M
Intrexon XON:US USD 1.58M 234K
IONIS PHARMACEUT IONS:US USD 1.52M 3.23M
JAZZ PHA JAZZ:US USD 133.66M 9.45M
Mannkind MNKD:US USD 17.46M 4.54M
Nektar Therapeutics NKTR:US USD 4.97M 143K
Peregrine Pharmaceuticals PPHM:US USD 27.58M 3.33M
Pfizer PFE:US USD 6.09B 2.58B
Rigel Pharmaceuticals RIGL:US USD 250K 786K
United Therapeutics UTHR:US USD 37.2M 7.5M
Vanda Pharmaceuticals VNDA:US USD 6.32M 261K